ArticleFrontiers in cardiovascular medicine2026
Interleukin-6 as a novel biomarker for the diagnosis of acute decompensated heart failure: a retrospective study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin-6 (IL-6) is associated with the pathogenesis of heart failure (HF) and an increased HF risk in people without previous myocardial infarction. However, little is currently known about the correlation between IL-6 and acute decompensated heart failure (ADHF). Objective: To determine whether IL-6 could serve as a diagnostic biomarker for ADHF in Chinese patients without acute myocardial infarction. Patients and methods: A total of 122 patients were included in our study [58 ADHF, 64 chronic HF (CHF)]. Plasma IL-6 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured. Logistic regression analyses and a receiver operating characteristic (ROC) curve were performed to determine the diagnostic value of IL-6. Results: Plasma levels of IL-6 and NT-proBNP were higher in ADHF patients than CHF patients. IL-6 correlated positively with NT-proBNP, heart rate, and left ventricular end-diastolic dimension, and inversely with left ventricular ejection fraction. After adjustment, IL-6 remained independently associated with ADHF (OR = 1.461, 95% CI: 1.053-2.028, Conclusions: IL-6 is independently associated with ADHF and shows promising diagnostic accuracy. The cut-off of 5.00 pg/mL provides a novel reference for Chinese ADHF patients without AMI, offering clinical evidence for research on inflammation-related biomarkers of cardiovascular diseases. Combined use with NT-proBNP may enhance diagnostic accuracy, but prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.